What is the share price of Gufic Biosciences Ltd (GUFICBIO) today?
The share price of GUFICBIO as on 18th July 2025 is ₹384.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Gufic Biosciences Ltd (GUFICBIO) share?
The past returns of Gufic Biosciences Ltd (GUFICBIO) share are- Past 1 week: 7.77%
- Past 1 month: 3.60%
- Past 3 months: 11.86%
- Past 6 months: -15.35%
- Past 1 year: 9.72%
- Past 3 years: 91.24%
- Past 5 years: 335.09%
What are the peers or stocks similar to Gufic Biosciences Ltd (GUFICBIO)?
The peers or stocks similar to Gufic Biosciences Ltd (GUFICBIO) include:What is the dividend yield % of Gufic Biosciences Ltd (GUFICBIO) share?
The current dividend yield of Gufic Biosciences Ltd (GUFICBIO) is 0.03.What is the market cap of Gufic Biosciences Ltd (GUFICBIO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gufic Biosciences Ltd (GUFICBIO) is ₹3865.20 Cr as of 18th July 2025.What is the 52 week high and low of Gufic Biosciences Ltd (GUFICBIO) share?
The 52-week high of Gufic Biosciences Ltd (GUFICBIO) is ₹504.25 and the 52-week low is ₹298.80.What is the PE and PB ratio of Gufic Biosciences Ltd (GUFICBIO) stock?
The P/E (price-to-earnings) ratio of Gufic Biosciences Ltd (GUFICBIO) is 55.49. The P/B (price-to-book) ratio is 7.26.Which sector does Gufic Biosciences Ltd (GUFICBIO) belong to?
Gufic Biosciences Ltd (GUFICBIO) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Gufic Biosciences Ltd (GUFICBIO) shares?
You can directly buy Gufic Biosciences Ltd (GUFICBIO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Gufic Biosciences Ltd
GUFICBIO Share Price
GUFICBIO Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
GUFICBIO Performance & Key Metrics
GUFICBIO Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
55.50 | 7.26 | 0.03% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
37.08 | 6.54 | 0.76% |
GUFICBIO Analyst Ratings & Forecast
Price Upside
Earnings Growth
Rev. Growth
GUFICBIO Company Profile
Gufic Biosciences Limited manufactures pharmaceuticals, medicinal chemicals and botanical products. The Company's segments include Formulations, Bulk Drugs and Consumer.
GUFICBIO Forecast
GUFICBIO Forecasts
GUFICBIO
GUFICBIO
Income
Balance Sheet
Cash Flow
GUFICBIO Income Statement
GUFICBIO Income Statement
Financial Year | FY 2024 | FY 2025 | TTM | |||
---|---|---|---|---|---|---|
Total Revenue | 808.85 | 823.43 | 823.43 | |||
Raw Materials | 389.32 | 685.11 | 685.11 | |||
Power & Fuel Cost | 17.79 | |||||
Employee Cost | 109.63 | |||||
Selling & Administrative Expenses | 103.90 | |||||
Operating & Other expenses | 40.15 | |||||
EBITDA | 148.06 | 138.32 | 138.32 | |||
Depreciation/Amortization | 17.02 | 21.06 | 21.07 | |||
PBIT | 131.04 | 117.26 | 117.25 | |||
Interest & Other Items | 15.36 | 23.11 | 23.11 | |||
PBT | 115.68 | 94.15 | 94.14 | |||
Taxes & Other Items | 29.54 | 24.49 | 24.50 | |||
Net Income | 86.14 | 69.66 | 69.64 | |||
EPS | 8.59 | 6.95 | 6.94 | |||
DPS | 0.10 | 0.10 | 0.10 | |||
Payout ratio | 0.01 | 0.01 | 0.01 |
GUFICBIO Company Updates
Investor Presentation
GUFICBIO Stock Peers
GUFICBIO Past Performance & Peer Comparison
GUFICBIO Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Gufic Biosciences Ltd | 55.49 | 7.26 | 0.03% |
Sun Pharmaceutical Industries Ltd | 37.40 | 5.64 | 0.94% |
Cipla Ltd | 22.71 | 3.83 | 1.08% |
Torrent Pharmaceuticals Ltd | 62.06 | 15.63 | 0.91% |
GUFICBIO Stock Price Comparison
Compare GUFICBIO with any stock or ETFGUFICBIO Holdings
GUFICBIO Shareholdings
GUFICBIO Promoter Holdings Trend
GUFICBIO Promoter Holdings Trend
GUFICBIO Institutional Holdings Trend
GUFICBIO Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
GUFICBIO Shareholding Pattern
GUFICBIO Shareholding Pattern
GUFICBIO Shareholding History
GUFICBIO Shareholding History
Mutual Funds Invested in GUFICBIO
Mutual Funds Invested in GUFICBIO
No mutual funds holding trends are available
Top 5 Mutual Funds holding Gufic Biosciences Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3379% | Percentage of the fund’s portfolio invested in the stock 0.99% | Change in the portfolio weight of the stock over the last 3 months -0.13% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 46/59 (-7) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9419% | Percentage of the fund’s portfolio invested in the stock 0.95% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 30/34 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4149% | Percentage of the fund’s portfolio invested in the stock 0.19% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 97/130 (0) |
Compare 3-month MF holding change on Screener
smallcases containing GUFICBIO stock
smallcases containing GUFICBIO stock
Looks like this stock is not in any smallcase yet.
GUFICBIO Events
GUFICBIO Events
GUFICBIO Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
GUFICBIO Dividend Trend
No dividend trend available
GUFICBIO Upcoming Dividends
GUFICBIO Upcoming Dividends
No upcoming dividends are available
GUFICBIO Past Dividends
GUFICBIO Past Dividends
Cash Dividend
Ex DateEx DateSep 17, 2024
Dividend/Share
₹0.10
Ex DateEx Date
Sep 17, 2024
Cash Dividend
Ex DateEx DateSep 21, 2023
Dividend/Share
₹0.10
Ex DateEx Date
Sep 21, 2023
Cash Dividend
Ex DateEx DateAug 24, 2022
Dividend/Share
₹0.10
Ex DateEx Date
Aug 24, 2022
Cash Dividend
Ex DateEx DateSep 9, 2021
Dividend/Share
₹0.10
Ex DateEx Date
Sep 9, 2021
Cash Dividend
Ex DateEx DateNov 3, 2020
Dividend/Share
₹0.05
Ex DateEx Date
Nov 3, 2020
GUFICBIO Stock News & Opinions
GUFICBIO Stock News & Opinions
Gufic BioSciences has appointed Rajesh Kaul as Senior President - Sparsh Cluster, Senior Management Personnel of the Company with effect from 04 July 2025. Powered by Capital Market - Live
Net profit of Gufic BioSciences declined 61.50% to Rs 7.72 crore in the quarter ended March 2025 as against Rs 20.05 crore during the previous quarter ended March 2024. Sales rose 5.14% to Rs 205.02 crore in the quarter ended March 2025 as against Rs 194.99 crore during the previous quarter ended March 2024. For the full year,net profit declined 19.14% to Rs 69.65 crore in the year ended March 2025 as against Rs 86.14 crore during the previous year ended March 2024. Sales rose 1.63% to Rs 819.81 crore in the year ended March 2025 as against Rs 806.67 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales205.02194.99 5 819.81806.67 2 OPM %12.8717.55 -16.4318.08 - PBDT18.3731.46 -42 115.21132.69 -13 PBT10.5227.12 -61 94.14115.67 -19 NP7.7220.05 -61 69.6586.14 -19 Powered by Capital Market - Live
Net profit of Gufic BioSciences declined 60.25% to Rs 7.97 crore in the quarter ended March 2025 as against Rs 20.05 crore during the previous quarter ended March 2024. Sales rose 5.14% to Rs 205.02 crore in the quarter ended March 2025 as against Rs 194.99 crore during the previous quarter ended March 2024. For the full year,net profit declined 18.82% to Rs 69.93 crore in the year ended March 2025 as against Rs 86.14 crore during the previous year ended March 2024. Sales rose 1.63% to Rs 819.81 crore in the year ended March 2025 as against Rs 806.67 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales205.02194.99 5 819.81806.67 2 OPM %12.9917.55 -16.4618.08 - PBDT18.6131.46 -41 115.48132.70 -13 PBT10.7727.12 -60 94.42115.68 -18 NP7.9720.05 -60 69.9386.14 -19 Powered by Capital Market - Live
Gufic BioSciences announced that the Board of Directors of the Company at its meeting held on 30 May 2025, inter alia, have recommended the final dividend of Rs 0.1 per equity Share (i.e. 10%) , subject to the approval of the shareholders.Powered by Capital Market - Live
Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live
Net profit of Gufic BioSciences declined 13.21% to Rs 19.32 crore in the quarter ended December 2024 as against Rs 22.26 crore during the previous quarter ended December 2023. Sales rose 2.98% to Rs 207.79 crore in the quarter ended December 2024 as against Rs 201.78 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales207.79201.78 3 OPM %16.3418.07 - PBDT30.9033.70 -8 PBT26.2829.56 -11 NP19.3222.26 -13 Powered by Capital Market - Live
Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter. Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review. EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24. Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.Powered by Capital Market - Live
Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter. Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review. EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24. Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant. The scrip rose 1.95% o settle at Rs 446.65 on Thursday, 14 November 2024, the domestic stock market to remain closed today on account of Guru Nanak Jayanti.Powered by Capital Market - Live
Net profit of Gufic BioSciences declined 6.16% to Rs 21.78 crore in the quarter ended September 2024 as against Rs 23.21 crore during the previous quarter ended September 2023. Sales declined 4.98% to Rs 204.18 crore in the quarter ended September 2024 as against Rs 214.87 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales204.18214.87 -5 OPM %18.9218.32 - PBDT33.5735.24 -5 PBT29.2730.94 -5 NP21.7823.21 -6 Powered by Capital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant